Jonathon Vallejo

Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis.

Oladimeji Akinboro, Jonathon Vallejo, Erica C. Nakajima et al. · Journal of Clinical Oncology · 2022 · 77 citations

FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia

Dianne Pulte, Jonathon Vallejo, Donna Przepiorka et al. · The Oncologist · 2018 · 56 citations · Full text

Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis.

Erica C. Nakajima, Yi Ren, Jonathon Vallejo et al. · Journal of Clinical Oncology · 2022 · 54 citations

Advanced Nsclc, Pd-l1 Expression, Medicine +15

FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy

Donna Przepiorka, Robert Q. Le, Alexei Ionan et al. · Clinical Cancer Research · 2022 · 50 citations · Full text

Pediatric Patients 12, Pharmacotherapy, Pre-clinical Pharmacology +17

Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis.

Oladimeji Akinboro, Jonathon Vallejo, Pallavi S. Mishra‐Kalyani et al. · Journal of Clinical Oncology · 2021 · 48 citations

Pd-l1-positive Nsclc, Advanced Nsclc, Chemotherapy Versus Immunotherapy +13